Answers are grounded in this paper and cite their sources.
Case report demonstrates targeted reirradiation safety challenges in lung adenocarcinoma following prior breast radiation.
Background Reirradiation of thoracic malignancies presents significant clinical challenges due to cumulative lung dose and radiation-induced toxicity risk. With the advent of advanced modalities such as helical tomotherapy (HT), precise targeting may allow safe reirradiation in select cases. We report a case of locally advanced lung adenocarcinoma managed with accelerated HT and concurrent capecitabine after prior breast radiation, highlighting the complexities of dose overlap and treatment toxicity. Case Report A 73-year-old female with a remote history of left breast carcinoma (lumpectomy and adjuvant radiation in the 1990s, reirradiated for local recurrence in 2020) and prior heavy tobacco use presented with cough and chest discomfort. Imaging revealed a 2.4 cm left lower lobe mass with mediastinal and hilar lymphadenopathy, consistent with AJCC 8th Edition cT1cN3M0 Stage IIIB adenocarcinoma. Molecular testing: PD-L1 TPS 20%, ALK-, ROS1-, pan-TRK-. She received concurrent chemoradiation with helical tomotherapy (HT) and capecitabine (Xeloda). After 25 fractions, therapy was held due to progressive pleural effusions causing alignment errors. She later developed chronic pleural effusions, acute limb ischemia, and pulmonary embolism, ultimately opting for comfort care. Discussion This case underscores the complexities of thoracic reirradiation, particularly in patients with prior breast irradiation and significant smoking history. The overlapping dose to previously irradiated lung segments likely contributed to radiation-induced lung injury and impaired drainage leading to recurrent effusions. Advanced image-guided platforms like HT improve precision, yet toxicity remains a concern when cumulative V20 and mean lung dose exceed tolerance thresholds. Conclusion Helical tomotherapy with concurrent capecitabine can be considered in select thoracic reirradiation scenarios; however, careful dose mapping, multidisciplinary review, and vigilant toxicity monitoring are essential. This case illustrates the delicate balance between local control and pulmonary tolerance in reirradiation of lung malignancies.
No takes yet. Share an insight, caveat, or question.
Gulraiz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: